Skip to content

Investments at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
AbbVie logo
AbbVieABBV
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's investments?
TG Therapeutics (TGTX) reported investments of $61.54M in Q1 2026.
How has TG Therapeutics's investments changed year-over-year?
TG Therapeutics's investments increased by 3127.0% year-over-year, from $1.91M to $61.54M.
What is the long-term trend for TG Therapeutics's investments?
Over 4 years (2021 to 2025), TG Therapeutics's investments has grown at a 13.6% compound annual growth rate (CAGR), from $35.53M to $59.14M.